Evidence map›Paper›PMID 34739846›Full record

ArticleCancer cell2021

Adoptive transfer of tumor-specific Th9 cells eradicates heterogeneous antigen-expressing tumor cells.

Kevin Sek, Cheok Weng Chan, Paul A Beavis, Phillip K Darcy

Abstract readComment
PubMed Publisher
In one paragraph

Article in Cancer cell, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. T cells in health and disease.Signal transduction and targeted therapy · 2023
    Review
  2. Review
  3. Review
  4. Cancer-Homing CAR-T Cells and Endogenous Immune Population Dynamics.International journal of molecular sciences · 2021
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Kevin SekCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne 3000, VIC, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville 3010, Australia.
Cheok Weng ChanCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne 3000, VIC, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville 3010, Australia.
Paul A BeavisCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne 3000, VIC, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville 3010, Australia. Electronic address: paul.beavis@petermac.org.
Phillip K DarcyCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne 3000, VIC, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville 3010, Australia; Department of Pathology, University of Melbourne, Parkville 3010, Australia; Department of Immunology, Monash University, Clayton, Australia. Electronic address: phil.darcy@petermac.org.
Peter MacCallum Cancer Centre · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this issue of Cancer Cell, Xue et al. demonstrate that adoptive transfer of tumor-specific Th9 cells can eradicate established tumors containing antigen-loss-variant cells (ALVs) through both direct killing and bystander effects mediated by intratumoral accumulation of extracellular ATP (eATP) that promotes monocyte infiltration and stimulation of IFNα/β production.

Indexed as

NeoplasmsAdoptive TransferHumans

Identifiers

PMID34739846
OpenAlexW3210315139

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.